184 results on '"Gerardi, Calogera"'
Search Results
2. Prognostic value of multiparametric cardiac magnetic resonance in sickle cell patients
3. Phenotypic Clustering of Thalassemia Intermedia Patients Using Cardiovascular Magnetic Resonance
4. Phenotypic Clustering of Beta-Thalassemia Intermedia Patients Using Cardiovascular Magnetic Resonance
5. P1467: THE EMPLOYMENT OF DIRECT ORAL ANTICOAGULANTS IN PATIENTS AFFECTED BY Β-THALASSEMIA: A MULTICENTER ANALYSIS FROM THE EXTENSION-MYOCARDIAL IRON OVERLOAD IN THALASSEMIA NETWORK (E-MIOT)
6. Multicenter validation of the magnetic resonance T2* technique for quantification of pancreatic iron
7. Kiosk 9R-TA-12 - Phenotypic Clustering of Thalassemia Intermedia Patients Using Cardiovascular Magnetic Resonance
8. Multi-Parametric Cardiac Magnetic Resonance for Prediction of Heart Failure Death in Thalassemia Major
9. Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?
10. Fast generation of T2⁎ maps in the entire range of clinical interest: Application to thalassemia major patients
11. Prognostic value of multiparametric cardiac magnetic resonance in sickle cell patients
12. Longitudinal changes in LIC and other parameters in patients receiving different chelation regimens: Data from LICNET
13. Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major
14. Serial echocardiographic left ventricular ejection fraction measurements: A tool for detecting thalassemia major patients at risk of cardiac death
15. The era of comparable life expectancy between thalassaemia major and intermedia: Is it time to revisit the major‐intermedia dichotomy?
16. Hematopoietic peripheral circulating blood stem cells as an independent marker of good transfusion management in patients with β-thalassemia: results from a preliminary study
17. Extramedullary hematopoiesis is associated with lower cardiac iron loading in chronically transfused thalassemia patients
18. Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial
19. Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies
20. Cardiac complications and diabetes in thalassaemia major: a large historical multicentre study
21. Right Ventricular Volumes and Function normalized to body surface area, age and sex in a large cohort of well-treated Thalassemia Major without myocardial iron overload
22. Association between Native Myocardial T1 Mapping and Cardiac Function and Macroscopic Fibrosis in Thalassemia Major
23. CMR T2* technique for segmental and global quantification of myocardial iron: multi-centre transfereability and healtcare impact evalaution
24. Feasibility, reproducibility, and reliability for the T*2 iron evaluation at 3 T in comparison with 1.5 T
25. Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients
26. Longitudinal follow‐up of patients with thalassaemia intermedia who started transfusion therapy in adulthood: a cohort study
27. LIC-R2 Values Predict Severity of SCD: Baseline Data from Licnet-S
28. Correlation between Changes in Cardiac Iron and Hepatic Iron in Pediatric Patients with Thalassemia Major
29. Long-term sequential deferiprone–deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial
30. Influence of Myocardial Fibrosis and Blood Oxygenation on Heart T2* Values in Thalassemia Patients
31. Multicenter Validation of the Magnetic Resonance T2* Technique for Quantification of Pancreatic Iron
32. Multicenter validation of the magnetic resonance T2* technique for quantification of pancreatic iron
33. Relationship between uric acid levels and cardiometabolic findings in a large cohort of β-thalassemia major patients
34. Inadequacy of Ferritin Trends for Predicting Changes in LIC Risk Category in Transfusion Depedent and Well Chelated Patients with Haemoglobinopathies
35. Longitudinal changes in LIC and other parameters in patients receiving different chelation regimens: Data from LICNET
36. Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?
37. Comment on 'deferiprone versus deferoxamine in thalassemia intermedia: results from a 5-year long-term Italian multicenter randomized clinical trial'
38. The era of comparable life expectancy between thalassaemia major and intermedia: Is it time to revisit the major-intermedia dichotomy?
39. Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?
40. Real-life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET
41. Different Thresholds of Serum Ferritin Levels for Prediction of Liver Iron Concentration in Hemoglobinopathies
42. Survival Comparability Between Thalassemia Major Versus Thalassemia Intermedia
43. Hematopoietic Peripheral Circulating Blood Stem Cells As an Independent Marker of Good Transfusion Management in Patients with Beta-Thalassemia
44. Deferiprone Versus Deferoxamine in Thalassemia Intermedia: Results from 5-Year Long-Term Italian Multi-Center Randomized Clinical Trial
45. Feasibility, reproducibility, and reliability for the T*2 iron evaluation at 3 T in comparison with 1.5 T
46. Long-Term Use of Deferiprone Enhances Significantly the Left Ventricular Ejection Function in Thalassemia Major
47. Feasibility, Reproducibility and Reliability for the T2* Iron Evaluation At 3T in Comparison with 1.5T
48. Left Ventricular Volumes, Mass and Function Normalized to the Body Surface Area, Age and Gender From CMR in a Large Cohort of Well-Treated Thalassemia Major Patients without Myocardial Iron Overload
49. Repeated Echocardiographic Left Ventricular Ejection Fraction Measurements: A Strong and Accessible Tool for Detecting At High Risk of Heart Failure Thalassemia Major Population,
50. Sequential Alternating Deferiprone And Deferoxamine Treatment Compared To Deferiprone Monotherapy: Main Findings And Clinical Follow-Up Of A Large Multicenter Randomized Clinical Trial In -Thalassemia Major Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.